Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 10

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Hepatol. Oct 27, 2014; 6(10): 759-765
Published online Oct 27, 2014. doi: 10.4254/wjh.v6.i10.759

Full Size Figure Download Figure

Figure 1 Flow chart of systematic review of protease inhibitor based triple therapy.

Citation: Mechie NC, Röver C, Cameron S, Amanzada A. Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. World J Hepatol 2014; 6(10): 759-765
URL: https://www.wjgnet.com/1948-5182/full/v6/i10/759.htm
DOI: https://dx.doi.org/10.4254/wjh.v6.i10.759

Mechie NC, Röver C, Cameron S, Amanzada A. Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. World J Hepatol 2014; 6(10): 759-765 [PMID: 25349647 DOI: 10.4254/wjh.v6.i10.759]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.